Effect of glucose feeding on the glycosylation quality of antibody produced by a human cell line, F2N78, in fed-batch culture.

Appl Microbiol Biotechnol

Department of Biological Sciences, KAIST, 335 Gwahak-ro, Yuseong-gu, Daejeon, 305-701, Korea,

Published: April 2014

The human cell line rF2N78 produces an antibody with a high galactosylation ratio which resembles human IgG. However, it has been observed that the aglycosylated antibody starts to appear when glucose is depleted. To determine whether glucose depletion is a main cause for aglycosylation of the antibody, fed-batch cultures of rF2N78 cells were performed using different feeding cocktails (glucose only, nutrient feeding cocktail without glucose, and nutrient feeding cocktail with glucose). In the fed-batch culture with nutrient feeding cocktail without glucose, aglycosylated antibody was produced in a later phase of culture, when glucose was depleted. Approximately 44 % of antibodies produced were aglycosylated at the end of culture. In contrast, aglycosylated antibody was not produced in cultures with glucose feeding. The expression levels of oligosaccharyl transferases determined by Western blot analysis were similar among the cultures, suggesting that aglycosylation of the antibody was not due to altered expression of oligosaccharyl transferases under glucose-deficient conditions. Thus, it is likely that glucose deficiency led to insufficiency of the precursor for glycosylation and induced aglycosylation of the antibody. Taken together, glucose feeding in fed-batch cultures successfully prevented occurrence of aglycosylated antibody during the cultures, confirming that glucose depletion is a main cause for aglycosylation of antibody.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00253-013-5462-0DOI Listing

Publication Analysis

Top Keywords

aglycosylated antibody
16
aglycosylation antibody
16
glucose
12
glucose feeding
12
antibody produced
12
nutrient feeding
12
feeding cocktail
12
cocktail glucose
12
antibody
10
human cell
8

Similar Publications

Monoclonal antibodies (mAbs) are a major class of biopharmaceuticals manufactured by well-established processes using Chinese Hamster Ovary (CHO) cells. Next-generation biomanufacturing using alternative hosts like Komagataella phaffii could improve the accessibility of these medicines, address broad societal goals for sustainability, and offer financial advantages for accelerated development of new products. Antibodies produced by K.

View Article and Find Full Text PDF

Fcγ receptors (FcγR) are responsible for many of the interactions between immunoglobulins (IgG) and immune cells. In biomedicine, this interplay is critical to the activity of several types of immunotherapeutics; however, relatively little is known about how FcγRs affect the in vivo performance of radiolabeled antibodies. A handful of recent preclinical studies suggest that binding by FcγR-and particularly FcγRI-can affect the pharmacokinetic profiles of Zr-labeled radioimmunoconjugates, but there are no extant studies in immunocompetent or genetically engineered mouse models of cancer.

View Article and Find Full Text PDF

evaluation of the role of Fab glycosylation in cetuximab antibody dynamics.

Front Immunol

August 2024

Analytical Excellence and Program Management, Merck Serono S.p.A., Rome, Italy.

Introduction: N-glycosylation is a post-translational modification that is highly important for the development of monoclonal antibodies (mAbs), as it regulates their biological activity, particularly in terms of immune effector functions. While typically added at the Fc level, approximately 15-25% of circulating antibodies exhibit glycosylation in the Fab domains as well. To the best of our knowledge, cetuximab (Erbitux) is the only therapeutic antibody presenting Fab glycosylation approved world-wide targeting the epidermal growth factor receptor for the treatment of metastatic-colorectal and head and neck cancers.

View Article and Find Full Text PDF
Article Synopsis
  • The self-association of therapeutic antibodies can lead to high viscosity, complicating manufacturing and limiting subcutaneous delivery, with previous solutions focusing on variable domain mutations and excipients.
  • This study examined various Fc mutations on the viscosity of two IgG antibodies: omalizumab (anti-IgE) and trastuzumab (anti-HER2), revealing that certain Fc modifications significantly reduced omalizumab's high viscosity (from 176 cP).
  • Molecular dynamics simulations provided insights into how these Fc mutations affect the antibodies' electrostatic and hydrophobic properties, suggesting that optimizing Fc mutations could improve future antibody therapies for easier subcutaneous administration.
View Article and Find Full Text PDF

Prostate-specific antigen (PSA) levels are widely used to screen for prostate cancer, yet the test has poor sensitivity, specificity and predictive value, which leads to overdiagnosis and overtreatment. Alterations in the glycosylation status of PSA, including fucosylation, may offer scope for an improved biomarker. We sought to generate a monoclonal antibody (mAb) targeting α-1,6-fucosylated PSA (fuc-PSA) and to develop a tissue-based immunological assay for fuc-PSA detection.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!